-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$39.671639.91% Upside
Recent Analyst Forecasts and Stock Ratings
Fate Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Fate Therapeutics, Inc.?
Fate Therapeutics, Inc. has been rated by research analysts at BMO Capital, Stifel Nicolaus, Piper Sandler, H.C. Wainwright, Canaccord Genuity, Goldman Sachs in the past 90 days.